Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Chengxiao Zheng"'
Autor:
Yan Zhang, Lu Zhang, Xian Zhang, Xin Yao, Tingyu Wang, Dan Zhu, Liping Lan, Peihua Lu, Yihong Yao, Lugui Qiu, Xiaoyan Qu, Gang An, Weiwei Sui, Junfang Yang, Jiaqi Huang, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Daobin Zhou, Jianyong Li
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study developed C
Externí odkaz:
https://doaj.org/article/68b5531b55cd4978b5a00d2f1fdf0450
Autor:
Xiaoyan Qu, Gang An, Weiwei Sui, Tingyu Wang, Xian Zhang, Junfang Yang, Yan Zhang, Lu Zhang, Dan Zhu, Jiaqi Huang, Shigui Zhu, Xin Yao, Jing Li, Chengxiao Zheng, Kevin Zhu, Yutiang Wei, Xiaoteng Lv, Liping Lan, Yihong Yao, Daobin Zhou, Peihua Lu, Lugui Qiu, Jianyong Li
BackgroundAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor-T cell (CAR T) therapy shows remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). C-CAR088, a novel second-generation humanized anti-BCMA CAR T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe478c0e8f0543870102ac44ea4634b0
https://doi.org/10.21203/rs.3.rs-1468511/v1
https://doi.org/10.21203/rs.3.rs-1468511/v1
Autor:
Xiaoyan Qu, Gang An, Weiwei Sui, Tingyu Wang, Xian Zhang, Junfang Yang, Yan Zhang, Lu Zhang, Dan Zhu, Jiaqi Huang, Shigui Zhu, Xin Yao, Jing Li, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Liping Lan, Yihong Yao, Daobin Zhou, Peihua Lu, Lugui Qiu, Jianyong Li
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005145
BackgroundAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study developed C-
Autor:
Tingyu Wang, Judy Zhu, Li Zhang, Zhu Shigui, Michael J. Humphries, Junfang Yang, Xian Zhang, Liping Lan, Xiuxiu Yan, Dingzhu Yang, Daobin Zhou, Yihong Yao, Gang An, Jiaqi Huang, Peihua Lu, Jianyong Li, Junfeng Wu, Weiwei Sui, Xiaoyan Qu, Xiaoteng Lv, Shichao Qin, Ningning Huo, Lu Zhang, Yan Zhang, Dijun Zhao, Xin Yao, Chengxiao Zheng, Jiaqiang Ren, Ting Han
Publikováno v:
Blood. 136:29-30
Background: C-CAR088, an anti-BCMA CAR T-cell therapy is a novel 2nd generation 4-1BB chimeric antigen receptor T (CAR-T) cell therapy targeting BCMA which is specifically and highly expressed on multiple myeloma (MM) cells. C-CAR088 is manufactured
Autor:
Jiaqi Huang, Lili Zhou, Wei Yutian, Chengxiao Zheng, Junbang Wang, Xin Yao, Aibin Liang, Yi Hong, Michael J. Humphries, Chen Ye, Jie Liu, Wenjun Zhang, Wangqin Shu, Shiguang Ye, Dan Zhang, Shicheng Chen, Jiaqiang Ren, Xiaochen Tang, Ping Li, Rirfei Wang, Yihong Yao, Liping Lan, Shiyi Chen, Li Zhang, Zhu Shigui, Judy Zhu
Publikováno v:
Blood. 136:8-9
Background: Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge of CD19 CAR-T therapy. These patients universally have poor outcomes. CD20 is a proven therapeutic target for B-Cell Non-Hodgkin Lymphomas (B-NHL), supporte
Autor:
Liping Lan, Michael J. Humphries, Ping Li, Jiaqi Huang, Wei Yutian, Zhu Shigui, Yangyang Xu, Judy Zhu, Aibin Liang, Shiguang Ye, Yihong Yao, Xiaoteng Lv, Xin Yao, Lili Zhou, Chengxiao Zheng, Shiyi Chen
Publikováno v:
Journal of Clinical Oncology. 39:2508-2508
2508 Background: Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge of CD19 CAR-T therapy. These patients universally have a poor outcome and the unmet medical need is high. CD20 is a proven therapeutic target for B-NHL
Autor:
Huilai Zhang, Jie Jin, Lili Zhou, Aibin Liang, Yangyang Xu, Liping Lan, Jing Zhao, Judy Zhu, Shiguang Ye, Ping Li, Jiaqi Huang, Kevin Zhu, Lanfang Li, Min Yang, Chengxiao Zheng, Jing Li, Yihong Yao, Daobin Zhou, Yan Zhang, Wenjuan Yu
Publikováno v:
Journal of Clinical Oncology. 39:2507-2507
2507 Background: C-CAR039 has been developed as a novel 2nd generation 4-1BB bi-specific CAR-T targeting both CD19 and CD20 antigens with an optimized bi-specific antigen binding domain. C-CAR039 can eradicate CD19/CD20 single or double positive tumo
Autor:
Jie Liu, Junbang Wang, Qingsong Zhang, Judy Zhu, Jiangqin Zheng, Xiaochen Tang, Shiyi Chen, Aibin Liang, Lili Zhou, Xin Yao, Yihong Yao, Wenjun Zhang, Chengxiao Zheng, Michael J. Humphries, Yi Hong, Lin Guo, Jiaqiang Ren, Shiguang Ye, Liping Lan, Li Yanfeng, Rirfei Wang, Shicheng Chen, Jiaqi Huang, Li Zhang, Zhu Shigui, Ping Li
Publikováno v:
Blood. 136:8-8
Background: Aiming to improve both the response rate and durability of response while limiting antigen escape of CD-19 following anti-CD-19 CAR-T therapy, C-CAR039 has been developed as a 2nd generation 4-1BB novel bi-specific chimeric antigen recept